Profil

DUBOIS Sophie

Département de médecine interne > Service d'hématologie clinique

See author's contact details
Main Referenced Co-authors
Beguin, Yves  (44)
Baron, Frédéric  (43)
Ehx, Grégory  (30)
Hannon, Muriel  (30)
Caers, Jo  (20)
Main Referenced Keywords
GVHD (10); Th17 (9); NSG (5); NSG mice (5); Azacytidine (3);
Main Referenced Unit & Research Centers
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège [BE] (9)
Giga-Infection, Immunity and Inflammation Laboratoire d'hématologie (8)
GIGA I3-Hematology - ULiège [BE] (1)
Giga-Haematology (1)
Main Referenced Disciplines
Hematology (33)
Biochemistry, biophysics & molecular biology (13)
Immunology & infectious disease (2)
Oncology (1)
Anatomy (cytology, histology, embryology...) & physiology (1)

Publications (total 49)

The most downloaded
538 downloads
Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003 https://hdl.handle.net/2268/144697

The most cited

62 citations (Scopus®)

Briquet, A., Dubois, S., Bekaert, S., Dolhet, M., Beguin, Y., & Gothot, A. (2010). Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID -repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica, 95 (1), 47-56. doi:10.3324/haematol.2009.008524 https://hdl.handle.net/2268/80211

Faville, C.* , E Silva, B.* , Jassin, M., DUBOIS, S., Daulne, C., Cobraiville, G., De Voeght, A., Baron, F., Fillet, M.* , & Ehx, G.*. (06 February 2024). Discovery And Targeting of Persister-specific Antigens in Acute Myeloid Leukemia [Poster presentation]. Télévie Seminar.
* These authors have contributed equally to this work.

Faville, C.* , E Silva, B.* , Jassin, M., DUBOIS, S., Daulne, C., Cobraiville, G., De Voeght, A., Baron, F., Fillet, M.* , & Ehx, G.*. (06 February 2024). Discovery And Targeting of Persister-specific Antigens in Acute Myeloid Leukemia [Paper presentation]. Télévie Seminar.
* These authors have contributed equally to this work.

Beguin, C., Kwan, O., Ritacco, C., Debray, J.-C., Dejardin, E., Dubois, S., Köse, M. C., Canti, L., Courtois, J., Seidel, L., Daulne, C., Caers, J., Beguin, Y., Ehx, G., & Baron, F. (17 November 2023). TNF-α priming of human regulatory T cells does not increase their ability to prevent xenogeneic graft-versus-host disease [Paper presentation]. Congrès annuel de la Société Francophone de Greffe de Moelle et Thérapie Cellulaire, Lille, France.
Peer reviewed

E Silva, B., Faville, C., Jassin, M., DUBOIS, S., De Voeght, A., Baron, F., & Ehx, G. (09 September 2023). Characterizing the immune recognition of chemo-persister blasts in acute myeloid leukemia [Poster presentation]. GIGA Day 2023.

Ritacco, C., Köse, M. C., Courtois, J., Canti, L., Beguin, C., DUBOIS, S., Vandenhove, B., Servais, S., Caers, J., Beguin, Y., Ehx, G.* , & Baron, F.*. (17 March 2023). Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. iScience, 26 (3), 106085. doi:10.1016/j.isci.2023.106085
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1
Peer Reviewed verified by ORBi

Ehx, G.* , Ritacco, C.* , HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Ritacco, C., Ehx, G., Canti, L., DUBOIS, S., Vandenhove, B., SERVAIS, S., Beguin, Y., & Baron, F. (01 March 2020). Ptcy Prevents Xenogeneic Gvhd without Abrogating Gvl Effects. Biology of Blood and Marrow Transplantation, 26 (3), 168. doi:10.1016/j.bbmt.2019.12.028
Peer Reviewed verified by ORBi

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007
Peer Reviewed verified by ORBi

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619
Peer Reviewed verified by ORBi

Muller, J., Duray, E., Lejeune, M., DUBOIS, S., Plougonven, E., Léonard, A., Storti, P., Giuliani, N., Cohen-Solal, M., Hempel, U., Thijssen, V., BEGUIN, Y., Heusschen, R., & CAERS, J. (2019). Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts. Cancers, 11 (2), 261. doi:10.3390/cancers11020261
Peer Reviewed verified by ORBi

Muller, J., Bolomsky, A., Dubois, S., Duray, E., Stangelberger, K., Plougonven, E., Lejeune, M., Léonard, A., Marty, C., Hempel, U., Baron, F., BEGUIN, Y., Cohen-Solal, M., Ludwig, H., Heusschen, R., & CAERS, J. (2018). Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity on multiple myeloma bone disease. Haematologica, 103, 1359-1368. doi:10.3324/haematol.2017.185397
Peer Reviewed verified by ORBi

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease [Poster presentation]. 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., Beguin, Y., & Baron, F. (27 March 2017). Xenogeneic graft-versus-host disease : Impact of Th17 cells [Poster presentation]. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France.

Ehx, G., Hannon, M., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (March 2017). Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease. Biology of Blood and Marrow Transplantation, 23 (3), 365–S366. doi:10.1016/j.bbmt.2016.12.314
Peer Reviewed verified by ORBi

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (February 2017). Impact of Th17 population on xenogeneic graft-versus-host disease [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Muller, J., BINSFELD, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2017). Galectin-1 decreases during osteoclast formation [Poster presentation]. 44th Annual European Calcified Tissue Society Congress, Austria.

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425
Peer Reviewed verified by ORBi

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (08 December 2016). Xenogeneic graft-versus-host disease: Impact of Th17 cells [Poster presentation]. Journée des chercheurs Télévie 2017, Bruxelles, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (18 November 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. Congrès Commun de la SFGM-TC et de la SFBCT, Liège, Belgium.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique [Paper presentation]. 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium.

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Delens, L., BEGUIN, Y., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., SERVAIS, S., & BARON, F. (27 May 2016). Th17 cell population seems to aggravate xenogeneic graft-versus-host disease [Poster presentation]. 2016 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (March 2016). Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 22 (3), 393. doi:10.1016/j.bbmt.2015.11.917
Peer Reviewed verified by ORBi

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (28 February 2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 2nd Herbert Fleisch Workshop, Brugge, Belgium.

Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (29 January 2016). Salt but not glucocorticoïds enhances Th17 differentiation from naïve T cells in vitro [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Ehx, G., Hannon, M., Humblet-Baron, S., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., & BARON, F. (29 January 2016). Immunomodulatory effects of rapamycin in Graft versus Host Disease [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Delens, L., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., DELVENNE, P., BEGUIN, Y., Conteduca, G., & Baron, F. (29 January 2016). Azacytidine and Decitabine prevent experimental sclerodermic chronic graft-versus-host disease [Poster presentation]. 31st general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

Heusschen, R.* , Muller, J.* , Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., BEGUIN, Y., Menu, E., Cohen-Solal, M., & CAERS, J. (2016). SRC Kinase Inhibition with Saracatinib Limits the Development of Osteolytic Bone Disease in Multiple Myeloma. Oncotarget, 7, 30712-30729. doi:10.18632/oncotarget.8750
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., BEGUIN, Y., Heusschen, R., & CAERS, J. (2016). Galectin-1 is involved in osteoclast biology [Poster presentation]. 43rd Annual European Calcified Tissue Society Congress, Rome, Italy.

Heusschen, R., Muller, J., Binsfeld, M., Marty, C., Plougonven, E., DUBOIS, S., Mahli, N., Moermans, K., Carmeliet, G., Léonard, A., BARON, F., Cohen-Solal, M., Vanderkerken, K., BEGUIN, Y., Menu, E., & CAERS, J. (2016). SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma [Paper presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Brussels, Belgium.

Delens, L., Servais, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Daulne, C., Vrancken, L., Beguin, Y., & Baron, F. (03 December 2015). Revisiting Th17 cell subsets in the setting of allogeneic stem cell transplantation and (cortico-refractory) graft-versus-host disease [Poster presentation]. Journée Télévie 2016, Gembloux, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., Delvenne, P., BEGUIN, Y., Conteduca, G., & Baron, F. (19 November 2015). L'Azacytidine comme traitement de la maladie du greffon contre l'hôte de type chronique sclérodermique expérimentale [Paper presentation]. 15ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire, Clermont-Ferrand, France.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (13 November 2015). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. EORTC Leukemia Group-GIMEMA meeting, Rome, Italy.

Delens, L., SERVAIS, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Beguin, Y., & Baron, F. (30 January 2015). Effects of Tocilizumab on Th17 cell differentiation in a humanized mouse model of xenogeneic graft-versus-host disease [Poster presentation]. 30st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Muller, J., Binsfeld, M., DUBOIS, S., Carmeliet, G., Beguin, Y., Heusschen, R., & CAERS, J. (2015). The anti-angiogenic peptide Anginex blocks osteoclastogenesis. Belgian Journal of Hematology, Abstracts book.
Peer Reviewed verified by ORBi

Ehx, G., HANNON, M., DUBOIS, S., HALLEUX, A., Belle, L., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (27 January 2014). Immunomodulatory effects of Rapamycin in xenogeneic GVHD [Poster presentation]. GIGA Day 2014, Liège, Belgium.

Fransolet, G., Belle, L., SOMJA, J., Humblet-Baron, S., DUBOIS, S., Delvenne, P., Beguin, Y., & Baron, F. (January 2014). Imatinib improves survival of chronic Graft-versus-host disease by inhibiting TGF-β and PDGF-R in mice [Poster presentation]. 29th general annual meeting of the Belgian Hematological Society, Ghent, Belgium.

Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Belle, L., BINSFELD, M., DUBOIS, S., Hannon, M., Caers, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (February 2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin. Biology of Blood and Marrow Transplantation, 19, 317.
Peer Reviewed verified by ORBi

Binsfeld, M., Otjacques, E., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & CAERS, J. (2013). The Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 41.

Menten, C., Faccinetto, C., Golovchenko, M., Dupiereux-Fettweis, I., Van Lerberghe, P.-B., DUBOIS, S., Desmet, C., Elmoualij, B., Baron, F., Rudenko, N., Oury, C., Heinen, E., & Couvreur, B. (December 2012). Neutrophil Extracellular Traps (NET) Entrap and Kill Borrelia burgdorferi sensu stricto Spirochetes and Are not Affected by Ixodes ricinus Tick Saliva. Journal of Immunology, 189 (11), 5393-5401. doi:10.4049/jimmunol.1103771
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., Briquet, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice [Paper presentation]. 38th EBMT Annual Meeting.

Binsfeld, M., Belle, L., Hannon, M., DUBOIS, S., Otjacques, E., Beguin, Y., Baron, F., & CAERS, J. (2012). Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice [Paper presentation]. 27th General Meeting of the Belgian Hematological Society.

Bruck, F., Baron, F., DUBOIS, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., Beguin, Y., & Humblet-Baron, S. (February 2011). Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells [Poster presentation]. ASBMT meeting 2011. doi:10.1016/j.bbmt.2010.12.535

Briquet, A., Dubois, S., Bekaert, S., Dolhet, M., Beguin, Y., & Gothot, A. (2010). Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID -repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica, 95 (1), 47-56. doi:10.3324/haematol.2009.008524
Peer Reviewed verified by ORBi

Contact ORBi